Biotech & AI drug discoveryNature Medicine

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Nature Medicine reports the phase 2a GDFATHER-NEO trial evaluating neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer. Specific results are not provided in the available context.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-24T00:00:00+00:00

Published here2026-10-25T21:52:30+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04740-9

Original headline

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.